Skip to main content
Premium Trial:

Request an Annual Quote

Intrexon Raises $1M in VC Cash for Subcellular Genetic Tools

NEW YORK, March 3 (GenomeWeb News) -- Intrexon Corporation has closed a $1 million round of private-equity financing to advance its subcellular tools and related marketing initiatives, the company said this week.


"This financing will enable us to expand our capabilities and offerings in the emerging market for subcellular inhibition tools," Robert Beech, Intrexon's CEO said in a statement.


The financing was provided by NewVa Capital Partners, a regional investment partnership managed by Third Security. NewVa last made an investment in Intrexon in May 2005.


Intrexon has used previous investment funds to research, develop, and validate a set of DNA vectors that target selected kinases in primary subcellular locations. These vectors are now available from the company as mDECOY kits, Intrexon said.

The Scan

Booster Push

New data shows a decline in SARS-CoV-2 vaccine efficacy over time, which the New York Times says Pfizer is using to argue its case for a booster, even as the lower efficacy remains high.

With Help from Mr. Fluffington, PurrhD

Cats could make good study animals for genetic research, the University of Missouri's Leslie Lyons tells the Atlantic.

Man Charged With Threatening to Harm Fauci, Collins

The Hill reports that Thomas Patrick Connally, Jr., was charged with making threats against federal officials.

Nature Papers Present Approach to Find Natural Products, Method to ID Cancer Driver Mutations, More

In Nature this week: combination of cryogenic electron microscopy with genome mining helps uncover natural products, driver mutations in cancer, and more.